Update on inflammatory breast cancer

Florence Lerebours, Ivan Bieche, Rosette Lidereau, Florence Lerebours, Ivan Bieche, Rosette Lidereau

Abstract

Inflammatory breast cancer (IBC) is both the least frequent and the most severe form of epithelial breast cancer. The diagnosis is based on clinical inflammatory signs and is reinforced by pathological findings. Significant progress has been made in the management of IBC in the past 20 years. Yet survival among IBC patients is still only one-half that among patients with non-IBC. Identification of the molecular determinants of IBC would probably lead to more specific treatments and to improved survival. In the present article we review recent advances in the molecular pathogenesis of IBC. A more comprehensive view will probably be obtained by pan-genomic analysis of human IBC samples, and by functional in vitro and in vivo assays. These approaches may offer better patient outcome in the near future.

References

    1. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol. 1992;10:1014–1024.
    1. Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer. 1998;82:2366–2372.
    1. Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist. 2003;8:141–148. doi: 10.1634/theoncologist.8-2-141.
    1. Fleming RY, Asmar L, Buzdar AU, McNeese MD, Ames C, Ross MI, Singletary SE. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997;4:452–461.
    1. Arun B, Slack R, Gehan E, Spitzer T, Meehan KR. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer. 1999;85:93–99.
    1. Bertucci F, Tarpin C, Charafe-Jauffret E, Bardou VJ, Braud AC, Tallet A, Gravis G, Viret F, Goncalves A, Houvenaeghel G, et al. Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment. Bone Marrow Transplant. 2004;33:913–920. doi: 10.1038/sj.bmt.1704458.
    1. Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R, Jr, Shibata S, Chu P, Forman S, Lim D, et al. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol. 2004;22:1839–1848. doi: 10.1200/JCO.2004.10.147.
    1. Anderson WF, Chu KC, Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol. 2003;21:2254–2259. doi: 10.1200/JCO.2003.07.082.
    1. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2000;2:423–429. doi: 10.1186/bcr89.
    1. Paradiso A, Tommasi S, Brandi M, Marzullo F, Simone G, Lorusso V, Mangia A, De Lena M. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer. 1989;64:1922–1927.
    1. Brenner B, Siris N, Rakowsky E, Fenig E, Sulkes A, Lurie H. Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers. Br J Cancer. 2002;87:1404–1410. doi: 10.1038/sj.bjc.6600616.
    1. Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol. 2004;202:265–273. doi: 10.1002/path.1515.
    1. Henderson MA, McBride CM. Secondary inflammatory breast cancer: treatment options. South Med J. 1988;81:1512–1517.
    1. Piera JM, Alonso MC, Ojeda MB, Biete A. Locally advanced breast cancer with inflammatory component: a clinical entity with a poor prognosis. Radiother Oncol. 1986;7:199–204.
    1. Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, Van De Vijver M, MacGrogan G, Shepherd L, Amaral N, Duval C, Drijkoningen R, et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol. 2003;14:406–413. doi: 10.1093/annonc/mdg108.
    1. Kleer CG, van Golen KL, Braun T, Merajver SD. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol. 2001;14:458–464. doi: 10.1038/modpathol.3880334.
    1. Turpin E, Bieche I, Bertheau P, Plassa LF, Lerebours F, de Roquancourt A, Olivi M, Espie M, Marty M, Lidereau R, et al. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene. 2002;21:7593–7597. doi: 10.1038/sj.onc.1205932.
    1. Bonnier P, Charpin C, Lejeune C, Romain S, Tubiana N, Beedassy B, Martin PM, Serment H, Piana L. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer. 1995;62:382–385.
    1. Amparo RS, Angel CD, Ana LH, Antonio LC, Vicente MS, Carlos FM, Vicente GP. Inflammatory breast carcinoma: pathological or clinical entity? Breast Cancer Res Treat. 2000;64:269–273. doi: 10.1023/A:1026512722789.
    1. Delarue JC, May-Levin F, Mouriesse H, Contesso G, Sancho-Garnier H. Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast. Br J Cancer. 1981;44:911–916.
    1. Aziz SA, Pervez S, Khan S, Kayani N, Azam SI, Rahbar MH. Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J. 2001;7:398–404. doi: 10.1046/j.1524-4741.2001.07604.x.
    1. Guerin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer. 1989;43:201–208.
    1. Prost S, Le MG, Douc-Rasy S, Ahomadegbe JC, Spielmann M, Guerin M, Riou G. Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer. 1994;58:763–768.
    1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996;2:811–814. doi: 10.1038/nm0796-811.
    1. Faille A, De Cremoux P, Extra JM, Linares G, Espie M, Bourstyn E, De Rocquancourt A, Giacchetti S, Marty M, Calvo F. p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer. 1994;69:1145–1150.
    1. Riou G, Le MG, Travagli JP, Levine AJ, Moll UM. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst. 1993;85:1765–1767.
    1. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA. 1992;89:7262–7266.
    1. McCarthy NJ, Yang X, Linnoila IR, Merino MJ, Hewitt SM, Parr AL, Paik S, Steinberg SM, Hartmann DP, Mourali N, et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res. 2002;8:3857–3862.
    1. Charpin C, Bonnier P, Khouzami A, Vacheret H, Andrac L, Lavaut MN, Allasia C, Piana L. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/ neu, pS2, cathepsin, ER and PR. Anticancer Res. 1992;12:591–597.
    1. Van den Eynden GG, Van der Auwera I, Van Laere S, Colpaert CG, van Dam P, Merajver S, Kleer CG, Harris AL, Van Marck EA, Dirix LY, et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat. 2004;85:13–22. doi: 10.1023/B:BREA.0000021028.33926.a8.
    1. Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer. 2004;10:6789–6795.
    1. Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, Goovaerts G, Dirix LY, van Dam P, Fox SB, et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer. 2003;88:718–725. doi: 10.1038/sj.bjc.6600807.
    1. Van der Auwera I, Benoy I, Elst H, Van Laere S, Van Marck EA, Colpaert C, Van Dam P, Vermeulen PB, Dirix LY. Quantitative study of the angiogenic profile of inflammatory and non-inflammatory breast cancer using real-time RT-PCR [abstract] Breast Cancer Res Treat. 2003;82:s135.
    1. Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, Ethier SP. Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer. 1999;81:1328–1334. doi: 10.1038/sj.bjc.6695007.
    1. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res. 1999;5:2511–2519.
    1. Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH. A novel human xenograft model of inflammatory breast cancer. Cancer Res. 1999;59:5079–5084.
    1. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, Sasaki H, Kasumi F, Yoshimoto M, Iwanaga T, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 2001;61:445–451.
    1. Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001;61:5231–5241.
    1. Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH. Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene. 2002;21:3631–3643. doi: 10.1038/sj.onc.1205389.
    1. Shirakawa K, Shibuya M, Heike Y, Takashima S, Watanabe I, Konishi F, Kasumi F, Goldman CK, Thomas KA, Bett A, et al. Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer. Int J Cancer. 2002;99:344–351. doi: 10.1002/ijc.10336.
    1. Lerebours F, Bertheau P, Bieche I, Driouch K, De The H, Hacene K, Espie M, Marty M, Lidereau R. Evidence of chromosome regions and gene involvement in inflammatory breast cancer. Int J Cancer. 2002;102:618–622. doi: 10.1002/ijc.10729.
    1. Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, Livant D, Merajver SD. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene. 2002;21:3172–3180. doi: 10.1038/sj.onc.1205462.
    1. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000;60:5832–5838.
    1. Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF, Merajver SD. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res. 2004;6:R110–R115. doi: 10.1186/bcr755.
    1. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene. 2001;20:2401–2412. doi: 10.1038/sj.onc.1204389.
    1. Liauw SL, Benda RK, Morris CG, Mendenhall NP. Inflammatory breast carcinoma: outcomes with trimodality therapy for non-metastatic disease. Cancer. 2004;100:920–928. doi: 10.1002/cncr.20083.
    1. Thomas F, Arriagada R, Spielmann M, Mouriesse H, Le Chevalier T, Fontaine F, Tursz T. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer. 1995;76:2286–2290.
    1. Chevallier B, Asselain B, Kunlin A, Veyret C, Bastit P, Graic Y. Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. Cancer. 1987;60:897–902.
    1. Rouesse J, Friedman S, Mouriesse H, Sarrazin D, Spielmann M. Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors. Breast Cancer Res Treat. 1990;16:15–22.
    1. Sarrazin D, Rouesse J, Arriagada R, May-Levin F, Petit JY, Contesso G. Breast cancers in the evolutive phase. Rev Prat. 1978;28:999–1009.
    1. Lerebours F, Bertheau P, Bieche I, Plassa LF, Champeme MH, Hacene K, Toulas C, Espie M, Marty M, Lidereau R. Two prognostic groups of inflammatory breast cancer have distinct genotypes. Clin Cancer Res. 2003;9:4184–4189.
    1. Palangie T, Mosseri V, Mihura J, Campana F, Beuzeboc P, Dorval T, Garcia-Giralt E, Jouve M, Scholl S, Asselain B, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer. 1994;7:921–927. doi: 10.1016/0959-8049(94)90115-5.
    1. Levine PH, Steinhorn SC, Ries LG, Aron JL. Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst. 1985;74:291–297.
    1. Wilke D, Colwell B, Dewar R. Inflammatory breast carcinoma: comparison of survival of those diagnosed clinically, pathologically, or with both features. Am Surg. 1998;64:428–431.
    1. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, Wagstaff J, Pinedo HM. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer. 1998;77:621–626.
    1. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–469.
    1. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995;4:715–734.
    1. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40:321–329. doi: 10.1007/s002800050664.
    1. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993;16:223–228.
    1. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986;46:2578–2581.
    1. Harris EE, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003;55:1200–1208. doi: 10.1016/S0360-3016(02)04201-3.
    1. Fields JN, Perez CA, Kuske RR, Fineberg BB, Bartlett N. Inflammatory carcinoma of the breast: treatment results on 107 patients. Int J Radiat Oncol Biol Phys. 1989;17:249–255.
    1. Perez CA, Fields JN, Fracasso PM, Philpott G, Soares RL, Jr, Taylor ME, Lockett MA, Rush C. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer. 1994;74:466–476.
    1. Villavicencio EH, Walterhouse DO, Iannaccone PM. The sonic hedgehog-patched-gli pathway in human development and disease. Am J Hum Genet. 2000;67:1047–1054.
    1. Oliver TG, Grasfeder LL, Carroll AL, Kaiser C, Gillingham CL, Lin SM, Wickramasinghe R, Scott MP, Wechsler-Reya RJ. Transcriptional profiling of the sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci USA. 2003;100:7331–7336. doi: 10.1073/pnas.0832317100.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever